HEALTH TECHNOLOGY

Vicarious Surgical Announces Center of Excellence Agreements with HCA Healthcare and UH Ventures to Advance System Design

Vicarious Surgical Inc. | July 08, 2022 | Read time : 3 min

Vicarious Surgical

Vicarious Surgical Inc. a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it has signed collaborative Center of Excellence agreements with both HCA Healthcare, one of the nation’s leading providers of healthcare services comprising 182 hospitals, and University Hospitals Ventures, the innovation and commercialization arm of University Hospitals (UH), a comprehensive health system with more than 20 hospitals, over 50 health centers, and over 200 physician offices in northern Ohio. As part of these agreements, HCA Healthcare and UH Ventures will each provide user input through their system physicians as the Company advances the design of its Vicarious Surgical Robot. Through these distinct collaborations, Vicarious Surgical will gain unique exposure to the detailed surgical workflows at each of these partners and incorporate direct surgeon and administrator feedback into its total product ecosystem to meet the needs of major US hospital systems. Additionally, clinical and human-centered design experts from both HCA Healthcare and UH will assist Vicarious Surgical to further enhance product design, helping ensure readiness for streamlined adoption upon FDA Approval.

Establishing our Center of Excellence model with two leading U.S. health systems offers significant validation of our system’s in-hospital potential and creates an incredible opportunity to integrate real-world surgeon experiences and feedback as we work toward our system’s finalization. These partnerships establish two powerful innovation conduits through which our team gains unprecedented access to understanding and addressing the complexities of surgical workflow and hospital integration while building commercial expertise. Meanwhile, our clinical partners – HCA Healthcare and University Hospitals – become the first health systems to access our minimally invasive surgical robot and directly influence its advancement. We could not be more excited to partner with two of the top institutions in the country as we progress on our path to improve surgery for patients, surgeons, hospitals, and payors.”

Adam Sachs, CEO and co-founder of Vicarious Surgical

“Our surgical and innovation teams are on the cutting edge of new care technologies designed to benefit patients,” said Dr. Joseph Sabik, Chairman, Department of Surgery at University Hospitals. “Collaborating with Vicarious Surgical on their Center of Excellence model for training and next generation surgical robotics provides our team a thrilling front row seat in the quest to improve the landscape for minimally-invasive surgery that enhances patient care and clinical outcomes.”

“University Hospitals’ goal is to be the most trusted health care partner in Northeast Ohio,” explained Kendra Gardiner, Director of Product Strategy for UH Ventures. “As part of this strategy, UH is dedicated to accelerating discovery, innovation and translation of scientific breakthroughs that address unmet clinical and social needs to enhance the lives of our patients, our communities and the world. We also aim to be the partner of choice by creating and sharing value together. This new relationship with Vicarious Surgical is one example of how we are advancing this objective.”

About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. 

About HCA Healthcare
Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 182 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. HCA Healthcare subsidiary Health Insight Capital makes equity investments in early-stage companies that are selected to provide innovative solutions for use in health system operations and is an investor in Vicarious Surgical. Please click here to connect with HCA Healthcare on social media.

About UH Ventures
UH Ventures is the innovation and commercialization arm of University Hospitals (UH), a comprehensive health system with annual revenues in excess of $5.0 billion, more than 20 hospitals, more than 50 health centers and outpatient facilities, and over 200 physician offices located throughout 16 counties. UH’s goal is to be the most trusted health care partner in Northeast Ohio and UH Ventures furthers this objective by shaping new products, services, experiences, and companies that improve the lives of patients and caregivers. To advance the UH mission, UH Ventures strives to support a diverse portfolio of value-adding opportunities in health care, enhance the distinct and unique capabilities of the system, and foster a culture of discovery, innovation, and entrepreneurship within UH and the larger community. For caregivers, UH Ventures provides the tools and resources needed to nurture, validate, and advance ideas sparked by day-to-day insights. For potential partners, UH Ventures seeks to be a dynamic living laboratory where both clinical and product insights can help accelerate emerging technologies tackling health care’s most pressing problems. 

Spotlight

Our Reach for the Stars solutions are designed to help you meet CMS Star Ratings attached to Medicare Part D plans, retain and grow your health plan relationships and find new innovative business opportunities.

Spotlight

Our Reach for the Stars solutions are designed to help you meet CMS Star Ratings attached to Medicare Part D plans, retain and grow your health plan relationships and find new innovative business opportunities.

Related News

HEALTH TECHNOLOGY

Medical Device Innovation Consortium Launches Initiative to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics

MDIC | August 23, 2022

The Medical Device Innovation Consortium formally launched its Somatic Reference Samples Initiative with a pilot project to improve the validation and regulatory review process for cancer diagnostics based on next generation sequencing. MDIC will lead a collaboration with the U.S. Food and Drug Administration the National Institute of Standards and Technology, National Institutes of Health and industry stakeholders to manufacture, validate, and distribute SRSs to simplify and support validation of NGS-based cancer diagnostics. The initiative also includes the goal to create a publicly available global genomic data resource library of datasets with the potential to be used by sponsors and regulators. “NGS is a powerful technology enabling breakthroughs in diagnostics and ultimately therapeutics. These diagnostic tests need to be validated for accurate clinical use, and reference samples are essential to the validation process. But well-characterized and widely accepted reference materials do not exist for NGS-based diagnostics, complicating the development and validation process. Through the MDIC SRS Initiative, we are developing reference samples and data sets that can be used globally by test developers and regulators to bring more consistency to NGS-based cancer diagnostic development, increasing the confidence and accuracy of these tests, which will ultimately lead to more accuracy in diagnosis and treatment for patients.” Andrew Fish, President and CEO, MDIC “There is a need for appropriately consented, highly characterized, and broadly available reference materials that may improve the accuracy, reliability, and transparency of NGS-based oncology tests and support the generation of validation data for use in regulatory submissions. The reference samples and datasets being created by the MDIC Somatic Reference Samples Initiative can help fulfill this need,” said Wendy Rubinstein, MD, PhD, Director, Personalized Medicine, Center for Devices and Radiological Health, U.S. Food and Drug Administration. Horizon Discovery, a PerkinElmer company, is conducting the development and manufacture of these reference samples. The goal of this pilot project is to individually engineer 10 gene variants clinically associated with cancer into a highly characterized human cell line – GM24385 using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology resulting in ten edited human cell lines, each containing one gene variant clinically associated with one or more specific cancers. The cell lines, containing confirmed sequences, will be combined and available in FFPE format. The fully characterized reference samples will be commercially available to the end users from Horizon and the characterization data will be accessible through public databases, including precisionFDA, an FDA-sponsored site for data information, sequencing, and bioinformatics. NIST’s involvement in this work is to foster understanding.* “As our collaboration validates the MDIC SRS samples, we will also learn and build best practices to improve the efficiency and sustainability of reference sample validation and dataset generation in general. This project is a major step in the development and optimization of new sequencing technologies and the translation of DNA sequencing to clinical applications for diagnosing and treating cancer,” said Justin Zook, PhD, Co-Leader, Biomarker and Genomic Sciences Group, National Institute of Standards and Technology. MDIC’s SRS project began as a working group in 2018, representing more than forty stakeholders with a mission to address the gap in reference material for NGS-based diagnostic tests. The initial output of this working group, MDIC’s SRS Landscape Analysis, published in 2019, was a comprehensive catalog of existing clinically relevant cancer variants and available reference samples. Based on the unmet needs discovered through the SRS Landscape Analysis, the SRS Initiative has prioritized a subset of ten variants to be engineered into reference samples for the pilot project. In addition to the utility of these samples in development, validation, and regulatory review, these samples potentially have value in reimbursement decisions, post-market monitoring and informing the path forward for addition SRS. The work in the SRS Initiative is funded in part by the Gordon and Betty Moore Foundation the National Philanthropic Trust, Illumina, and Quidel. Affiliation with a commercial product does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified are necessarily the best available for the purpose. About MDIC Founded in 2012, the Medical Device Innovation Consortium is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to transform health care into human care. Collaborating with our partners to advance science, we enable transformational medical technology to shape the world we want to live in and make that world possible by shortening the path from innovation to safety to access.

Read More

HEALTH TECHNOLOGY

Amazon and One Medical Sign an Agreement for Amazon to Acquire One Medical

One Medical | July 22, 2022

Amazon and One Medical announced that they have entered into a definitive merger agreement under which Amazon will acquire One Medical. One Medical is a human-centered, technology-powered national primary care organization on a mission to make quality care more affordable, accessible, and enjoyable through a seamless combination of in-person, digital, and virtual care services that are convenient to where people work, shop, and live. “We think health care is high on the list of experiences that need reinvention. Booking an appointment, waiting weeks or even months to be seen, taking time off work, driving to a clinic, finding a parking spot, waiting in the waiting room then the exam room for what is too often a rushed few minutes with a doctor, then making another trip to a pharmacy – we see lots of opportunity to both improve the quality of the experience and give people back valuable time in their days. We love inventing to make what should be easy easier and we want to be one of the companies that helps dramatically improve the healthcare experience over the next several years. Together with One Medical’s human-centered and technology-powered approach to health care, we believe we can and will help more people get better care, when and how they need it. We look forward to delivering on that long-term mission.” Neil Lindsay, SVP of Amazon Health Services “The opportunity to transform health care and improve outcomes by combining One Medical’s human-centered and technology-powered model and exceptional team with Amazon’s customer obsession, history of invention, and willingness to invest in the long-term is so exciting,” said Amir Dan Rubin, One Medical CEO. “There is an immense opportunity to make the health care experience more accessible, affordable, and even enjoyable for patients, providers, and payers. We look forward to innovating and expanding access to quality healthcare services, together.” Amazon will acquire One Medical for $18 per share in an all-cash transaction valued at approximately $3.9 billion, including One Medical’s net debt. Completion of the transaction is subject to customary closing conditions, including approval by One Medical's shareholders and regulatory approval. On completion, Amir Dan Rubin will remain as CEO of One Medical. About Amazon Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. About One Medical One Medical is a U.S. national human-centered and technology-powered primary care organization with seamless digital health and inviting in-office care, convenient to where people work, shop, live, and click. One Medical’s vision is to delight millions of members with better health and better care while reducing costs, within a better team environment. One Medical’s mission is to transform health care for all through a human-centered, technology-powered model. Headquartered in San Francisco, 1Life Healthcare, Inc. is the administrative and managerial services company for the affiliated One Medical physician-owned professional corporations that deliver medical services in-office and virtually. 1Life and the One Medical entities do business under the “One Medical” brand.

Read More

HEALTH TECHNOLOGY

Henry Schein Acquires Midway Dental Supply

Henry Schein, Inc. | August 30, 2022

Henry Schein, Inc. the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced the acquisition of Midway Dental Supply, a full-service dental distributor serving dental offices and dental laboratories across the Midwestern United States. Henry Schein acquired 100% of Midway Dental, which was founded in 1987 by the late Roger Abigt, and is headquartered in Livonia, Michigan. This transaction is expected to be modestly dilutive to Henry Schein’s earnings per share in fiscal year 2022 and increasingly accretive thereafter. Financial terms were not disclosed. Midway Dental’s sales from 2021 were approximately $110 million, including nearly $20 million in sales of personal protective equipment (PPE) and COVID-19 related products. Midway Dental offers a comprehensive portfolio of dental consumable merchandise, equipment, services, and education products to nearly 7,000 customers, which will be immediately consolidated into Henry Schein’s U.S. Dental business. The integration of Midway Dental’s sales and service team with Henry Schein’s network of trusted advisors will further advance the Company’s efforts to deliver customized solutions and technology-driven products and services to help our dental customers meet the needs of patients. “Over the past 35 years, Midway Dental has earned an excellent reputation within the industry, grounded by a strong commitment to customer service and industry leadership that is aligned with Henry Schein’s values-based culture and high-touch, full-service business model,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Midway Dental’s vision to establish a nationwide footprint aligns with Henry Schein’s commitment to provide the products and services customers can rely on to work more efficiently and deliver high-quality patient care more effectively.” Led by CEO Steven Kizy, Midway Dental has approximately 200 employees, including 55 sales representatives and 50 service technicians. Mr. Kizy will join Henry Schein as Vice President, Strategic Development-U.S. Dental. “As part of Henry Schein, Midway Dental will have access to new capabilities, including an expanded portfolio of solutions to serve our customers even better while offering our staff exciting new career possibilities. More specifically, Midway Dental’s customers will benefit from the vast array of Henry Schein branded products as well as the latest digital technologies that are modernizing dental practices. We are delighted to be joining forces with the world’s leading provider of dental products and services.” Mr. Kizy About Henry Schein, Inc. Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. With more than 22,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 32 countries and territories. The Company's sales reached $12.4 billion in 2021, and have grown at a compound annual rate of approximately 12.5 percent since Henry Schein became a public company in 1995.

Read More